PIKFYVE and melanoma: Nevertheless, analyses of melanoma, B-cell non-Hodgkin lymphoma and multiple myeloma cell lines reveal that a significant fraction (40% to 75%) are, on average, 14- to 26-fold more sensitive to PIKFYVE inhibitors than non-malignant cells [6,27,29].